Axcella Health Inc. (NASDAQ:AXLA – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 190,000 shares, a decrease of 44.2% from the December 31st total of 340,600 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.7% of the shares of the stock are short sold.
Institutional Trading of Axcella Health
Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its stake in Axcella Health by 1.1% during the second quarter. FMR LLC now owns 7,886,376 shares of the company's stock valued at $16,009,000 after buying an additional 85,541 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Axcella Health by 24.2% during the third quarter. Dimensional Fund Advisors LP now owns 113,085 shares of the company's stock valued at $194,000 after buying an additional 22,007 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Axcella Health by 13.9% during the second quarter. Renaissance Technologies LLC now owns 55,700 shares of the company's stock valued at $113,000 after buying an additional 6,800 shares in the last quarter. Thrivent Financial for Lutherans purchased a new stake in Axcella Health during the third quarter valued at about $67,000. Finally, Commonwealth Equity Services LLC purchased a new stake in Axcella Health during the third quarter valued at about $34,000. 71.05% of the stock is owned by hedge funds and other institutional investors.
Get Axcella Health alerts:Analysts Set New Price Targets
Several equities research analysts recently weighed in on the stock. Chardan Capital reduced their price objective on shares of Axcella Health from $7.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday, November 2nd. SVB Leerink reaffirmed a "market perform" rating and issued a $2.00 price objective (down previously from $6.00) on shares of Axcella Health in a report on Friday, December 16th. Wedbush reaffirmed an "outperform" rating and issued a $6.00 price objective on shares of Axcella Health in a report on Wednesday, November 2nd. Finally, HC Wainwright downgraded shares of Axcella Health from a "buy" rating to a "neutral" rating in a report on Thursday, December 15th.
Axcella Health Price Performance
NASDAQ AXLA traded down $0.08 on Friday, reaching $0.69. The company's stock had a trading volume of 980,012 shares, compared to its average volume of 1,709,592. Axcella Health has a twelve month low of $0.16 and a twelve month high of $2.89. The company has a debt-to-equity ratio of 2.33, a current ratio of 1.23 and a quick ratio of 1.23. The firm's 50 day moving average is $0.57 and its two-hundred day moving average is $1.40.Axcella Health (NASDAQ:AXLA – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. As a group, equities research analysts forecast that Axcella Health will post -1.39 EPS for the current fiscal year.
About Axcella Health
(Get Rating)
Axcella Health, Inc is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis.
See Also
- Get a free copy of the StockNews.com research report on Axcella Health (AXLA)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.